Answers are grounded in this paper and cite their sources.
Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132 .).
No takes yet. Share an insight, caveat, or question.
Dimopoulos et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: